miraDry: Underarm Evidence, Risks, and Recovery

miraDry is an in-office microwave treatment cleared by the FDA for primary axillary hyperhidrosis, meaning excessive sweating of the underarms. Its clearance does not extend to sweaty hands, feet, the face, generalized sweating, or sweating caused by another condition.[1] In the pivotal sham-controlled study, 89% of treated participants reached a lower symptom-severity category after 30 days, compared with 54% of the sham group.[2]

That is the useful answer behind the brand name: miraDry has controlled evidence for underarm sweating, but the evidence is narrower than a promise of complete or risk-free sweat elimination. Results varied, some participants received more than one session, and the best early studies followed people for 12 months rather than for life.

miraDry uses microwave energy at the sweat-gland layer#

The FDA's 510(k) summary describes a handpiece that delivers microwave energy while using vacuum and surface cooling. The target is tissue near the boundary between the skin and underlying fat, where many underarm sweat glands sit.[1] The procedure is prescription-use and intended for trained clinical administration.

FDA clearance is not the same as a guarantee that every person will respond. A 510(k) decision means the device was found substantially equivalent to a legally marketed predicate for its stated use. The agency's stated indication is treatment of primary axillary hyperhidrosis, and the clearance document expressly excludes other body areas and generalized hyperhidrosis.[1]

The pivotal trial found a clear short-term advantage over sham treatment#

The main randomized study enrolled 120 adults whose underarm sweating was severe enough to score 3 or 4 on the four-point Hyperhidrosis Disease Severity Scale, or HDSS. Eighty-one received active treatment and 39 received a sham procedure. At 30 days, 72 of 81 treated participants, or 89%, had an HDSS score of 1 or 2, compared with 21 of 39 participants, or 54%, in the sham group.[2]

The active group's response rate was 74% at three months and 69% at 12 months. That pattern supports a durable effect through the observed year, but it also shows why “permanent” should not be read as “everyone remains sweat-free.” The trial measured a defined symptom response, not total elimination of sweating, and follow-up ended at 12 months.[2]

A smaller study measured sweat and quality of life through 12 months#

A separate prospective study followed 31 adults after one to three treatment sessions. At the 12-month visit, 90.3% had an HDSS score of 1 or 2, 90.3% had at least a 50% reduction in measured underarm sweat, and 85.2% had improved by at least five points on the Dermatology Life Quality Index.[3]

Those numbers are encouraging, but the study was small and did not include a concurrent control group. Only 26 participants were represented in the published 12-month sweat-reduction figure. Miramar Labs funded the study, and one of its three authors was a company employee, an important conflict-of-interest disclosure when interpreting the findings. It is evidence of durability in a selected group, not proof that one session will produce the same result for every patient.[3]

Swelling, discomfort, and altered sensation were common in early studies#

All participants in the 31-person study experienced temporary treatment-area effects such as swelling, discomfort, or numbness. Twelve developed altered sensation in the skin of the arm; the study reported that it resolved in all 12.[3] In the randomized study, adverse events were generally described as mild, and all but one had resolved by the end of follow-up.[2]

These reports do not make the procedure consequence-free. A 2019 case report described bilateral brachial plexus injury after microwave treatment in one thin patient; the authors considered thermal injury likely, and substantial nerve injury remained on the right at the eight-month evaluation.[4] A single case cannot estimate how often this happens or establish the risk for a typical patient, but it shows why persistent weakness, radiating pain, or worsening numbness needs prompt clinical assessment rather than being dismissed as routine recovery.

Recovery burden belongs in the decision, alongside the possibility of repeat treatment. A consultation should distinguish expected local effects from a clinic's plan for evaluating symptoms that persist or worsen. Published studies also do not settle every question about rare harms or very long-term outcomes.

miraDry is an underarm option, not a general hyperhidrosis treatment#

The strongest evidence is for adults with primary, severe underarm sweating. Someone whose sweating is new, generalized, occurs mainly during sleep, or may be related to medication or another condition needs the cause assessed before a focal procedure is treated as the answer. A local device cannot address an underlying systemic cause.

For people comparing underarm options, the meaningful distinctions are treatment area, evidence, recovery, repeat-treatment burden, and access. Topical treatments and botulinum toxin have different mechanisms and follow-up patterns. miraDry's clinical evidence supports placing it on the underarm treatment map, not automatically ahead of every other option.

For the billing variables behind this procedure, see what a miraDry quote should include. The broader hyperhidrosis treatment evidence map compares the evidence boundaries of topical treatments, iontophoresis, injections, medicines, and procedures.

Bottom line#

miraDry has FDA clearance and randomized evidence for primary axillary hyperhidrosis. The pivotal trial found an 89% 30-day HDSS response with active treatment versus 54% with sham, with 69% of the active group still meeting the response definition at 12 months.[1][2] A smaller study found sustained measured-sweat and quality-of-life improvements, while also documenting common temporary swelling, discomfort, numbness, and altered sensation.[3]

This article is educational. It does not diagnose the cause of sweating or determine whether a procedure is appropriate for an individual.

References#

1. U.S. Food and Drug Administration. miraDry System 510(k) K103014 for primary axillary hyperhidrosis. FDA decision summary

2. Glaser DA, Coleman WP 3rd, Fan LK, et al. Randomized, blinded evaluation of a microwave device for axillary hyperhidrosis. Dermatologic Surgery. 2012. PubMed PMID 22289389

3. Hong HC, Lupin M, O'Shaughnessy KF. Clinical evaluation of a microwave device for treating axillary hyperhidrosis. Dermatologic Surgery. 2012;38(5):728-735. PubMed PMID 22452511 and PMC full text

4. Puffer RC, Bishop AT, Spinner RJ, Shin AY. Bilateral brachial plexus injury after MiraDry procedure for axillary hyperhidrosis. World Neurosurgery. 2019;124:370-372. PubMed PMID 30703585